## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kambiz Shekdar et al.

Application No. : 10/589,052

Confirmation No. : 5470

Filed or 371(c) Date : September 8, 2008

For : METHODS AND MATERIALS USING SIGNALING

**PROBES** 

Group Art Unit : 1639

Examiner : Amber D. Steele

New York, New York October 9, 2009

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following

documents:1

## **Foreign Patent Document**

CA 2,415,731<sup>2</sup> 01-24-2002 Praenadia GmbH

## **Non-Patent Document**

Kovala et al., "High-Efficiency Transfection of Endothelial Cells," FASEB 14:2486-2494 (2000).

A complete Form PTO/SB/08a listing these documents is attached hereto.

<sup>&</sup>lt;sup>2</sup> Canadian Patent Application No. 2,415,731 is said to be the Canadian counterpart of PCT Patent Publication No. WO 02/06524, which was made of record in the subject application in the August 2, 2007 Information Disclosure Statement.

Copies of these documents are enclosed herewith.

Applicants respectfully request that these documents be: (1) fully considered by the Examiner during the examination of this application; and (2) printed on any patent that may issue from this application. Applicants request that a copy of the enclosed Form PTO/SB/08a, as considered and marked by the Examiner, be forwarded to the undersigned with the next communication.

The items of information contained in this Supplemental Information Disclosure Statement were first cited in a communication from a foreign patent office in a counterpart application. This communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this Supplemental Information Disclosure Statement. Thus, the submission of this Statement does not affect any patent term adjustment. 37 C.F.R. § 1.704(d).

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is believed to be due. However, the Director is hereby authorized to charge any fee required, or credit any overpayment, in connection with this Statement, to Deposit Account No. 06-1075, Order No. 002298-0003-101.

Respectfully submitted,

/Jane T. Gunnison/

Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants ROPES & GRAY LLP Customer No. 81098 1211 Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000 Fax.: (617) 235-9492